Following his recent publication in the Lancet Respiratory Medicine, and presentation at the ERS Congress, we spoke with Prof. Liam Heaney (Queen’s University, Belfast, Northern Ireland, UK) about the composite biomarker approach to optimising steroid dosage in patients with severe asthma.
- Why is there a need for new approaches to optimising steroid dosage in people with severe asthma? (0:11)
- Could you give us a brief overview of the composite biomarker approach to optimising steroid dosage? (1:06)
- Could you tell us a little about your recent study comparing this approach with a symptomatic/risk/based algorithm? (2:23)
- What were the major findings of this study in terms of clinical and patient-reported outcomes? (4:19)
- What will be the impact of these findings on clinical practice and what future studies are planned? (6:10)
Speaker disclosure: Liam Heaney has received grant funding and taken part in advisory boards and given lectures at meetings supported by Hoffmann-La Roche–Genentech and Aerocrine. He has also taken part in asthma clinical trials sponsored by Hoffmann-La Roche–Genentech, and is an Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies, including Hoffman-La Roche and Aerocrine.
Support: Interview and filming supported by Touch Medical Media. Niche Science and Technology were given the opportunity to review the video. No changes to the video were made as a result.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!